bioecon Member area
Technology · Health & biomedicine / Regenerative & personalized medicine

Personalized & regenerative medicine

Gene and cell therapy platforms for rare monogenic and oncological diseases: AAV vectors, lentiviral HSC editing, ex vivo CRISPR (Casgevy) and in vivo CRISPR (LNP delivery) now deliver durable one-time treatments approved by FDA and EMA.

Maturity 4/9 Risk: medium Advanced therapies US · CN · EU Science: why it works → verified 2026-06-19 · 7 Sources (0 independent)

1 · What it gives

Personalized and regenerative medicine delivers durable, often one-time treatments by correcting or replacing disease-causing genetic defects at the cellular level. Four approved product classes now coexist: AAV gene replacement (Zolgensma $2.125M for SMA, Elevidys $3.2M for DMD), lentiviral HSC gene addition (Libmeldy, Strimvelis), ex vivo CRISPR editing of autologous stem cells (Casgevy $2.2M for sickle cell / beta-thal), and in vivo CRISPR via lipid nanoparticle delivery (Intellia lonvo-z Phase 3 positive in HAE, rolling BLA 2026). The global ATMPs market exceeded $5B in 2025 and is projected to reach $25B by 2030 at >30% CAGR. Manufacturing remains the dominant bottleneck: AAV vector production requires specialised cGMP bioreactor suites; ex vivo CRISPR requires patient-specific manufacturing windows of 4–8 weeks.

The key platforms of personalized & regenerative medicine are:

  1. AAV Gene Replacement (AAV Gene Therapy): single-stranded recombinant AAV vectors (serotypes rh74, AAV9) deliver a functional gene copy; one administration produces durable expression >3 years in SMA and DMD clinical data.
  2. Lentiviral HSC Gene Addition (Lentiviral Gene Therapy): ex vivo transduction of autologous haematopoietic stem cells; approved for ADA-SCID, MLD (OTL-200/Libmeldy) and X-ALD.
  3. Ex vivo CRISPR editing (CRISPR/Cas9 HSC): Cas9 knocks out BCL11A in autologous HSCs to reactivate foetal haemoglobin — basis of Casgevy (exa-cel), first CRISPR medicine approved by FDA (Dec 2023) and EMA.
  4. In vivo CRISPR via LNP (LNP-CRISPR): ionisable LNPs deliver Cas9 mRNA + sgRNA to hepatocytes; Intellia lonvo-z achieves >95% TTR knockdown in HAE (Phase 3 HAELO, 2026); clinical proof of concept for redosing demonstrated.

Sectoral value chain#

[patient biopsy / HSC harvest] ──> [vector mfg / cell engineering]
                                           │
                              (QC release, cGMP batch)
                                           │
                                           ▼
[patient] <─── [infusion / in vivo dosing] <─── [hospital treatment centre]

Value chain levels#

LevelDescriptionKey inputs/outputs
Cell/vector sourcingPatient HSC apheresis or AAV plasmid productionIn: patient or donor cells / plasmid DNA. Out: starting material.
Vector / gene construct manufacturingSuspension HEK293 triple-transfection (AAV) or lentiviral packaging; GMP bioreactor 200–2,000 LIn: plasmid, cells, bioreactor capacity. Out: crude viral vector harvest.
Purification & formulationAEX / CsCl ultracentrifugation for AAV; TFF + filtration for LV; fill into vialsIn: crude harvest. Out: GMP drug substance.
Patient cell engineering (ex vivo)HSC isolation, transduction / electroporation, expansion 14–21 daysIn: patient HSCs, vector / RNP. Out: engineered cell product.
QC releasePotency, sterility, identity, vector genome titre, RCV testing; 4–8 weeksIn: drug product. Out: released lot.
Administration & follow-upConditioning chemotherapy + infusion; ≥2 years safety monitoringIn: patient, released product. Out: treated patient + long-term outcome.

Cross-cutting technologies of the sector:

  • Lipid nanoparticles (LNP delivery): ionisable LNP enables in vivo hepatic delivery of mRNA/RNP; critical for in vivo CRISPR and personalised mRNA therapeutics.
  • Base editing / prime editing: precise single-nucleotide changes without DSB — next wave after Cas9; Beam Therapeutics and Prime Medicine advancing clinically.
  • Cell process automation: closed automated systems (CliniMACS Prodigy, Lonza Cocoon) reduce manual steps and enable decentralised manufacturing.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

  1. 1
    Plasmid and vector preparationStrains & cell linesFormulation & blending
    GMP plasmid DNA production (transfer vector, packaging plasmid, envelope plasmid) in E. coli fermentation at 10–200 L scale; or AAV ITR-flanked transfer plasmid; endotoxin <0.25 EU/mL specification.
    Who can do this step matched automatically
    Fermelanta Japan
    3,000 L pilot scale
    “is a Japan-based biomanufacturing/synthetic biology startup engineering fast-growing E.”
    Absolute India
    industrial scale
    “PHARMA: Biology-led APIs and peptides to improve scalability and accessibility of therapeutics, leveraging strain engineering, gene editing, and precision fermentation.”
    Tsingke Biotechnology China
    “Tsingke Biotech is a leader in synthetic biology, committed to building a world-class gene factory.”
    ToolGen (KOSDAQ) South Korea
    “Toolgen is committed to conducting research for revamping genome editing technology and thus developing not only therapeutics for humans but plants and animals of which the genetic …”
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “Platform and capabilities: end-to-end support from discovery to market approvals, with services spanning cell line creation, GMP/MO handling, CMC/PD/AD, MSAT …”
  2. 2
    Upstream manufacturingContract manufacturing (CMO/CDMO)
    HEK293 triple-transfection in 50–200 L stirred-tank bioreactor (AAV) or lentiviral packaging; Baculovirus/Sf9 platform for large-scale AAV; cell density 2–5 × 10⁶ cells/mL, harvest at 72–96 h post-transfection.
    Who can do this step matched automatically
    Space F South Korea
    “Space Rintec's Blueprint for Space CRO and CDMO - EDAILY — Space Rintech (Space Lintech) plans full-scale commercialization of its space CRO/CDMO business next year, targeting 10 …”
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and …”
    Ajinomoto Japan
    industrial scale
    “It remains highly active, focusing on its 2030 roadmap through business model transformation and expansion in CDMO services and high-value-added materials.”
    HLB Genex (ex-GenoFocus) South Korea
    industrial scale
    “Custom protein development and manufacturing: CDMO services with in-house contract manufacturing facilities for new protein development.”
    PBS Biotech United States
    ✓ ISO 9001 industrial scale
    “Trusted by leading biotech companies, academic institutions, and contract manufacturers worldwide, PBS Biotech is committed to simplifying cell therapy manufacturing while …”
    GenScript ProBio / Genscript China
    industrial scale
    “ProBio: subsidiary providing end-to-end CDMO services from drug discovery to commercialization, with focus on CGT, antibodies, and recombinant protein drugs to accelerate …”
  3. 3
    Downstream purificationPurification & downstream
    Iodixanol / CsCl ultracentrifugation or AEX + SEC chromatography for AAV; TFF + AEX for lentiviral; target: >1 × 10¹³ vg/mL, full/empty capsid ratio >90%, residual DNA <10 ng/dose.
    Who can do this step matched automatically
    Space F South Korea
    “2026-07-12 [Korea's next drug lab is in orbit - The Korea Herald — Space LiinTech is advancing Korea’s foray into space-based drug research with autonomous microgravity platforms …”
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “Adherent cell culture and downstream processing: commercialized Tide Motion bioreactor platform (MiniTide to TideXcell) with closed automated cell harvesting and single-use …”
    HLB Genex (ex-GenoFocus) South Korea
    industrial scale
    “With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”
    GenScript ProBio / Genscript China
    industrial scale
    “testing, including mass spectrometry and analytical high performance liquid chromatography”
    SilicoBio South Korea
    industrial scale
    “SilicoBio is a privately held KAIST faculty startup (South Korea) developing precision-fermentation cell factory platforms to scale microbial foods and functional ingredients …”
    Pivot Bio United States
    “Commercial AgronomySalesAccountingCorp FinanceITProduct ManufacturingDownstream Process DevelopmentDEPARTMENT”
  4. 4
    Cell engineering (ex vivo route)
    Patient HSC mobilisation (G-CSF + plerixafor), apheresis, CD34+ selection, electroporation of Cas9 RNP or lentiviral transduction; expansion 14–21 days; cell viability >80%, transduction efficiency >70%.
  5. 5
    QC release and fill-finishTesting & analyticsPackaging & fill-finish
    Potency assay (genome titre by ddPCR, transduction efficiency, HbF induction for Casgevy); sterility; identity (VCN, editing efficiency); replication-competent virus (RCV) testing; batch release 4–8 weeks; fill into cryobags or vials.
    Who can do this step matched automatically
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and …”
    Pakka (ex-Yash Pakka) India
    1940 MT per annum industrial scale
    “Pakka Limited (located in Ayodhya, India) provides regenerative packaging solutions for food products.”
    Mahyco India
    ✓ ISO 9001
    “Mahyco’s Seed Testing Laboratory at Dawalwadi has had the status of an ISTA-accredited Laboratory since April 2005 and is authorized to issue Orange, Green and Blue ISTA …”
    GenScript ProBio / Genscript China
    industrial scale
    “ProBio: A global CRDMO (contract research, development, and manufacturing organization) providing end-to-end solutions for biologics and cell and gene therapy (CGT).”
  6. 6
    Clinical administration
    Conditioning chemotherapy (busulfan myeloablation for HSC products); IV infusion or intrathecal injection (Itvisma); 2+ years safety follow-up per FDA/EMA requirement; patient outcome measured by disease biomarkers (VOCs, motor function scores, TTR levels).

4 · Who delivers

Matched suppliers (matched automatically)

PairwiseUnited StatesResearch / RTOactive
AbsoluteIndiaNot classifiedactive
ImpacFatSingaporeProduceractive
PBS BiotechUnited StatesServices / consultingactive
SartoriusGermanyProduceractive
MGI (BGI Group)ChinaProduceractive
BioConsortiaUnited StatesProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Intellia Therapeutics🇺🇸 USAlonvo-z / nex-zin vivo CRISPR LNPBLA rolling
CRISPR Therapeutics🇨🇭 SwitzerlandCasgevyex vivo CRISPR/Cas9Commercial
Sarepta Therapeutics🇺🇸 USAElevidysAAV rh74 micro-dystrophinCommercial
Orchard Therapeutics🇬🇧 UKOTL-200/201/203lentiviral HSC editingCommercial
Cellectis🇫🇷 Francelasme-cel (UCART22)TALEN allogeneic CAR-TPivotal
Novartis🇨🇭 SwitzerlandZolgensma / ItvismaAAV9 gene replacementCommercial

5 · Rules & route to market

United States

The US leads globally with >15 approved ATMPs and the largest clinical-stage pipeline; FDA issued Breakthrough and RMAT designations for >40 gene therapy programs in 2025 alone.

AAV approvals, CRISPR first approvals, RMAT pipeline#

  • Sarepta / Elevidys: FDA expanded Elevidys (delandistrogene moxeparvovec-rokl, AAV rh74) to all ambulatory and non-ambulatory DMD patients ≥4 years; 3-year EMBARK data shows sustained slowing of disease progression.
  • CRISPR Therapeutics + Vertex / Casgevy: first CRISPR medicine in history, FDA approved Dec 2023 for SCD and Jan 2024 for TDT; ~1,000 US patients ≥12 yr eligible; paediatric sNDA under review 2026.
  • Intellia / lonvo-z: Phase 3 HAELO data published New England Journal of Medicine (June 2026), rolling BLA submitted; US launch anticipated H1 2027 — first in vivo CRISPR therapy approaching approval.
European Union

Europe leads in lentiviral HSC gene therapy approvals (Libmeldy, Strimvelis, Skysona) and in allogeneic CAR-T development; ATMP regulation under EMA’s CAT committee is the gold standard globally.

EMA ATMP approvals, allogeneic CAR-T, Innovation Passport#

  • Orchard Therapeutics (Kyowa Kirin): OTL-200/Libmeldy EMA-approved for MLD; OTL-203 (MPS-I Hurler) completed registrational enrolment 1 year ahead of schedule; OTL-201 (MPS-IIIA) awarded Innovation Passport (UK ILAP) April 2026.
  • Novartis / Itvisma: positive CHMP opinion April 2026 for intrathecal onasemnogene abeparvovec for SMA patients ≥2 years — extends Zolgensma reach to older/heavier patients.
  • Cellectis / lasme-cel: FDA RMAT designation June 2026 for allogeneic TALEN-edited UCART22 in r/r B-ALL; Phase 1 100% response rate; pivotal trial initiated — only allogeneic CAR-T in a pivotal trial globally.
China

China is building a domestic gene therapy industry under NMPA’s accelerated ATMP pathway, with EdiGene and domestic CDMOs advancing CRISPR and viral vector programs.

NMPA ATMP pathway, domestic CRISPR, viral vector CDMOs#

  • EdiGene (博雅辑因): leading Chinese CRISPR gene editing company; ET-01 (base editing for beta-thalassaemia) in IND-enabling; CRISPR HSC programs under NMPA Fast Track.
  • Domestic vector CDMOs: WuXi Advanced Therapies, SinoGene providing AAV and lentiviral vector manufacturing for Chinese and global sponsors.
  • NMPA ATMP accelerated pathway: special approval category for innovative gene and cell therapies; priority review timeline 6–9 months for breakthrough designation.

6 · Money: tenders & grants

GrantAdvancing bio-printing of living cells for regenerative medicine
European Commission · EU
Sep 22, 2027
341 days

7 · Tech stack & innovations

The stack spans viral vector manufacturing, precision gene editing, and LNP delivery — each addressing a distinct disease class and manufacturing model.

  1. AAV gene replacement (AAV9 / rh74):
    • single-stranded recombinant AAV; serotype determines tissue tropism (AAV9 — CNS/muscle, rh74 — muscle); produced in HEK293 triple-transfection or baculovirus/Sf9.
    • Zolgensma maintains motor-function improvements >5 years post single IV dose in SMA Type 1.
  2. Ex vivo CRISPR/Cas9 (HSC editing):
    • patient HSCs mobilised, collected, edited (electroporation of Cas9 RNP), expanded, reinfused after myeloablative conditioning.
    • Casgevy: BCL11A enhancer knockout reactivates HbF >30%; >95% of SCD/TDT patients free from severe VOCs or transfusions at 24 months.
  3. In vivo LNP-CRISPR (hepatic delivery):
    • ionisable LNPs (~80 nm) deliver Cas9 mRNA + sgRNA after IV infusion; liver tropism enables knockdown of secreted disease proteins.
    • lonvo-z: >95% median TTR reduction in ATTR amyloidosis; redosing proof of concept demonstrated; HAELO Phase 3 showed >90% reduction in HAE attacks vs placebo.

Sources 7 · 0 independent · 7 producer sites

Producers' own sites 7

  1. Intellia therapeutics producer checked 2026-06-13 · link not kept
  2. Crispr therapeutics producer checked 2026-06-16 · link not kept
  3. Sarepta therapeutics producer checked 2026-03-19 · link not kept
  4. Orchard therapeutics producer checked 2026-05-03 · link not kept
  5. Cellectis producer checked 2026-06-15 · link not kept
  6. Edigene producer checked 2026-06-19 · link not kept
  7. Novartis producer checked 2026-04-26 · link not kept